» Articles » PMID: 21218461

Characteristics of the Coexistence of Melanoma and Renal Cell Carcinoma

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2011 Jan 11
PMID 21218461
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with melanoma (MM) have an increased risk of kidney cancer, and there is an excess risk of MM among patients with renal cell carcinoma (RCC). The objective of the current study was to analyze a series of 42 patients with both MM and RCC to identify clinical and pathologic features as well as risk factors of this association.

Methods: Clinical and pathologic characteristics of 42 patients who developed both MM and RCC (the MM + RCC series) were compared with 2 published series in each cancer alone: a series of 293 patients with MM (MM series) and a series of 1527 patients with RCC (RCC series).

Results: RCC was diagnosed concomitantly or after MM in 83% of patients in the MM + RCC series. Those patients displayed a high proportion of asymptomatic RCC at diagnosis (70%) and a higher frequency of stage I tumors (61%) than patients in the RCC series. Compared with the MM series, patients in the MM + RCC series more often were men, had a higher frequency of blond/red hair, had poor tanning ability, and had a higher number of nevi. In addition, patients in the MM + RCC series had a high aggregation of other malignancies (mainly skin cancers) and a significantly higher frequency of family history of MM (P = .005). Only 2 cyclin-dependent kinase 2A gene (CDKN2A) germline mutations were identified among patients in the MM + RCC series who also were members of MM-prone families.

Conclusions: The high aggregation of cancers among patients in the MM + RCC series and the familial clustering of MM argued for a genetic predisposition that may be partly independent of CDKN2A.

Citing Articles

Incidence of different types of cancer in the follow-up period after primary diagnosis and treatment of melanoma. Single-centre 4-year follow-up on a population of 709 patients.

Zietek M, Wierzbicki J, Nowacki M, Czajkowski R, Wronski P, Nowacka K Postepy Dermatol Alergol. 2023; 40(3):416-420.

PMID: 37545825 PMC: 10399667. DOI: 10.5114/ada.2023.127545.


Essential role of bromodomain proteins in renal cell carcinoma (Review).

Wen Q, Liu H, Lou K, Zhang X, Chao W, Xin J Mol Med Rep. 2023; 28(1).

PMID: 37293842 PMC: 10280547. DOI: 10.3892/mmr.2023.13026.


Identification of BRAF, CCND1, and MYC mutations in a patient with multiple primary malignant tumors: a case report and review of the literature.

Liu Z, Jin C, Zhang Y, Jiang Y, Wang J, Zheng L World J Surg Oncol. 2023; 21(1):158.

PMID: 37221610 PMC: 10207802. DOI: 10.1186/s12957-023-03036-3.


Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report.

Oprea A, Benas A, Havasi A, Gorzo A, Spinu S, Sur D Cureus. 2022; 14(6):e26359.

PMID: 35911362 PMC: 9329602. DOI: 10.7759/cureus.26359.


Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Sager R, Backe S, Ahanin E, Smith G, Nsouli I, Woodford M Nat Rev Urol. 2022; 19(5):305-320.

PMID: 35264774 PMC: 9306014. DOI: 10.1038/s41585-022-00571-8.